Pravin Karde’s Post

Oxford-based biotech startup Granza Bio, co-founded by Indian doctors Dr Ashwin Nandakumar and Dr Ashwin Jainarayanan, has secured over $7.14 million in seed funding to develop a groundbreaking cancer therapy. The startup, co-founded with renowned immunologist Professor Michael Dustin, is using the power of "attack particles" – the immune system's natural weapons against diseases like cancer, autoimmunity, and infections. By developing a precision delivery system for these particles, Granza Bio aims to transform the treatment of cancer and other diseases. “We are developing a series of precision delivery shells that can encompass and direct any therapeutic cargo to the correct destination in our body,” Dr Ashwin Nandakumar told biospace. Dr Nandakumar, CEO of Granza Bio, holds a PhD in Oncology and has previously set up clinical trials, while Dr Jainarayanan, CSO, has a PhD in Interdisciplinary Bioscience. Their collaboration with Prof Dustin, a leading expert in the field, has resulted in a powerful team dedicated to developing life-saving therapies. The fresh funding from investors including Felicis, Refactor, Y Combinator, and angel investors will accelerate Granza Bio's research and development efforts, bringing them closer to clinical trials and ultimately, to patients in need. #cancertherapy #seedfunding #healthcare #innovation #Kerala #Chennai [cancer therapy, medical research, Granza Bio, Dr Nandakumar, Dr Jainarayanan]

Paris, 14 June 2024 BREAKING NEWS! We are pleased to announce that Rosetta Omics has received the Bpifrance grant : BFT emergence to finance its deeptech program: two POCs studies in two solid tumors. BFT Emergence is a non-dilutive grant directed for deeptech startups to allow for the maximum financing of its R&D programs to reach the market. It is granted after a rigorous due diligence process of many months. The grant is part of the Deeptech plan financed by the France 2030 Program launched by the French State. Rosetta is a deeptech startup leading the way to precision medicine in oncology. We use spatial, multiomics (proteomics, metabolomics and lipidomics) and AI to predict the response to treatments in cancer patients and aid biopharma companies with patient stratification and biomarker discovery, and target validation. Many more great news in the pipeline, so stay tuned! #Bpifrance #fundraising #grants #oncology #cancer #multiomics #AI #ML #nondilutive #deeptech #proteomics #France2030 Agoranov Medicen Paris Region Paris Saclay Cancer Cluster (PSCC) France Biotech HealthTech For Care Choose Paris Region Région Ile de France La French Tech Les Deeptech 🚀 Agence de l'innovation en santé European Innovation Council and SMEs Executive Agency (EISMEA) EIT Health Hello Tomorrow Blue Factory ESCP BioLabs

Join us tomorrow at 7:30 PM at the start-up lounge with Mannheim Center for Entrepreneurship and Innovation by the Mannheim Business School; MARS - Center for Entrepreneurship and BioRN Life Science Cluster Rhine-Neckar. Panosome GmbH, a pioneering startup from #Heidelberg will be the main guest speaker for this event. They focus on revolutionizing the field of immunotherapy using its novel, proprietary VAST technology platform. This platform enables the generation of antibodies that target challenging disease markers, including small molecules, peptides, and proteins. Panosome's high on-target specificity ensures that its antibodies limit side effects, making treatments safer and more effective. The company's development pipeline is centered on addressing critical cancer indications with high unmet medical needs. Panosome is advancing the creation of monoclonal antibodies against tumor-specific carbohydrates, such as MUC1, to target pancreatic cancer, as well as T cell receptor-like antibodies aimed at intracellular cancer antigens. They are also applying their innovative approach to target mutations associated with midline glioma, a rare and aggressive brain cancer that primarily affects children. BioRN Life Science Cluster Rhine-Neckar is a science and industry innovation cluster that thrives on the constant interaction between academia, industry, and government to foster the production, transfer, and application of knowledge in the Life Sciences. Founded in 1996, BioRN uniquely brings together all the key innovation stakeholders in the Life Sciences around Heidelberg, situated at the junction of Baden-Württemberg, Rhineland-Palatinate, and Hesse, interconnected by the Rhein, Main, and Neckar rivers. The Heidelberg Biotech Simulator is a membership-only network that is designed to connect science and business students to both the AI & biotech industry and start-ups. They also offer our Master, PhD and Post-doc members the possibility to solve practical questions within start-ups, allowing you to experience what it is like to be a founder and acquire industry relevant skills. During this process you will receive feedback from venture capital and industry expert mentors. They offer plenty of events, workshops, CEO talks and socials. Join the network! https://lnkd.in/eE6YiRVE Stadt Heidelberg Technologiepark Heidelberg GmbH BioLabs Heidelberg

🚀 Startup News: Innovations from Atavistik Bio and Myriad Genetics These University of Utah startups continue to push the boundaries of innovation, providing solutions to some of today’s biggest unmet needs. Here’s the latest from two standout companies: 🔬 Atavistik Bio’s Precision Oncology Breakthrough Atavistik Bio has nominated ATV-1601, a selective allosteric small molecule inhibitor for AKT1 E17K-driven cancers, as their precision oncology development candidate. Using their AMPS™ technology and AI-powered drug discovery, they are advancing rapidly in cancer treatment. 🧬 Myriad Genetics x Flatiron Health Partnership Myriad Genetics is making genetic testing more accessible by integrating its MyRisk® Hereditary Cancer Test into Flatiron’s OncoEMR® platform. This means physicians can now seamlessly order and view results directly in their electronic medical records. 🤝 Myriad Genetics x jscreen™: Advancing Health Equity Myriad Genetics is partnering with jscreen™ to increase access to preventative genetic testing, focusing on high-risk populations and advancing health equity in precision medicine. Read more: https://lnkd.in/gcN-dZ4r #biotech #uofu #healthtech #innovation #genetictesting #precisionmedicine

#Biomixer #JPM2025 is ready to go !!! 🚀 The complete list of trailblazing startups selected to pitch at the Biomixer @ JPM 2025. These innovators are rewriting the future of biotech and healthcare: 🌟 1️⃣ Stealth-Co: Tackling refractory cancer with iPSC-derived immunological memory. 🌟 2️⃣ Toolkit to Examine Lifelike Language (TELL): AI-powered speech analysis transforming brain disorder diagnostics. 🌟 3️⃣ epiliquid: Making cancer detection accessible through liquid biopsy technology. 🌟 4️⃣ Narval: Pioneering a new generation of antibody therapeutics. 🌟 5️⃣ CellARTs: Empowering parenthood for men unable to be biological fathers. 🌟 6️⃣ Exogene: Generative AI driving T-cell-receptor-based cancer therapies. 🌟 7️⃣ TissueLabs: Revolutionizing cardiac health with bio-printed, engineered tissues. 🌟 8️⃣ The CellCo: Advancing next-gen biologic drugs. 🌟 9️⃣ NeuroSonic: Equipping doctors to stop strokes, anytime, anywhere. 🌟 🔟 Aptah Bio: Rejuvenating cells by restoring RNA expression and silencing toxic proteins.

Protein Design Startup Outpace Lands $144M to Test Treatments Targeting Solid Tumors https://lnkd.in/gUBrxQQk Outpace Bio, a Seattle-based startup using AI to design proteins for cancer therapies targeting solid tumors, has secured $144 million in new funding from investors. Outpace will utilize this funding to test its treatment in a clinical setting to confirm its approach to combating cancer. Co-founders Marc Lajoie and Scott Boyken met as postdoctoral fellows at the University of Washington’s Institute for Protein Design (IPD), which has an impressive record of producing biotech startups. With a total of $200 million raised to date, Outpace Bio is one of several homegrown startups emerging from Washington state’s premier research institutions. The post Protein Design Startup Outpace Lands $144M to Test Treatments Targeting Solid Tumors appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

𝐌𝐚𝐧𝐚𝐬 𝐀𝐈 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 $24.6𝐌 𝐭𝐨 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐰𝐢𝐭𝐡 𝐀𝐈 Manas AI, an AI-driven drug discovery startup, has raised $24.6 million in seed funding, backed by Reid Hoffman, General Catalyst, and Greylock Partners. The company is set to redefine cancer treatment by leveraging AI to analyze molecules 100 times faster than conventional methods—cutting drug development timelines from a decade to just a few years. Powered by Microsoft Azure’s cloud computing and AI expertise, Manas AI is collaborating with leading scientists, including Nobel laureates and National Academy members, to accelerate groundbreaking treatments for breast cancer, prostate cancer, and lymphoma. While its funding is smaller compared to Xaira Therapeutics ($1B) and Treeline Biosciences ($422M), Manas AI is focused on making a meaningful impact in precision-designed, AI-driven medicine. The funding announcement coincided with Reid Hoffman’s presentation for his latest book, Superagency: What Could Possibly Go Right with Our AI Future. 🚀 With cutting-edge AI and strong scientific partnerships, Manas AI is on a mission to revolutionize drug discovery and improve cancer treatment outcomes. #AI #HealthcareInnovation #DrugDiscovery #ManasAI #CancerResearch #StartupFunding

📢📰 Manas AI Secures $24.6M in Seed Funding 🗞️ 🔔 ➡️ LinkedIn founder Reid Hoffman and renowned cancer researcher Siddhartha Mukherjee have co-founded Manas AI, an AI-powered drug discovery startup that has raised $24.6 million in seed funding. The company will initially focus on developing novel treatments for breast cancer, prostate cancer, and lymphoma. Although this amount is relatively modest compared to other AI drug discovery startups, such as Xaira's $1 billion initial funding and Treeline Biosciences' $422 million, Manas AI's approach is noteworthy. 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: 1️⃣ Manas AI will leverage AI to design molecules, which will then be tested in a wet lab, marking a significant step in the drug discovery process 🧬 2️⃣ The startup will utilize Microsoft's Azure cloud computing platform and deep domain knowledge in AI to develop innovative medicines 🌐 3️⃣ Reid Hoffman's connection to Microsoft, which acquired LinkedIn in 2016, may play a crucial role in Manas AI's success 📈 4️⃣ The use of AI in drug discovery has the potential to revolutionize the pharmaceutical industry, enabling faster and more efficient development of novel treatments 🌟 5️⃣ Manas AI's focus on breast cancer, prostate cancer, and lymphoma highlights the urgent need for innovative solutions in these areas 🎗 6️⃣ The relatively modest funding amount may indicate a more measured approach to growth, allowing Manas AI to focus on developing a robust platform and pipeline 📊 #ArtificialIntelligence #DrugDiscovery #HealthcareInnovation #StartupFunding #PharmaceuticalIndustry Reference [https://lnkd.in/ggqqqy8H] 🔄 Share 👍 React 🌐 Visit aravind-r.com [www.aravind-r.com] Found this useful?, Share your comments below 👇

Berlin-based Lucid Genomics, co-founded by Uirá Souto Melo and M-Hossein Moeinzadeh, secures €1.3M in pre-seed round to advance AI-driven genomic diagnostics Lucid Genomics has raised €1.3 million in pre-seed funding led by caesar., with additional support from BIF Partners, another.vc, and the MPF Accelerator Program. This investment will accelerate the development of Lucid Genomics' AI-powered Digital HealthTech platform, which aims to revolutionize diagnostics and drug discovery by delivering precise insights from genomic data. The initial focus will be on rare genetic diseases, followed by a strategic expansion into cancer diagnostics and other related sectors. Jakob Hertzberg Nico Alavi Mojtaba Niazi Mariana Souto Tessa Remmers

Imagine a world where cancer treatment is as precise as GPS navigation! 🌍🔬 Scientists are making it possible with nanobots that travel through our bloodstream, targeting only cancer cells. 🎯💉 Through DNA origami – folding DNA into specific shapes – these tiny robots deliver treatment directly to cancer cells and activate only in areas with higher acidity, a hallmark of cancer cells. This means healthy cells stay safe, unlike traditional methods like chemotherapy, resulting in fewer side effects! 💪🧬 Why does this matter? Early lab tests on mice show a 70% reduction in tumor growth! 🐭✨ Though it's early, the potential impact is groundbreaking. Researchers are now advancing testing to ensure safety for future human trials, aiming to transform cancer treatment forever. 🚀💊 Could this be the future of medicine, fighting diseases at the cellular level? 🌱💥 #Innovation 🚀 #Technology 🔬 #FutureMedicine 💡 #HealthTech 🌐 #Startups 💼 #AnandNarayanan #AnikaTechnologies